Phathom Pharmaceuticals Inc. (PHAT) Announces Proposed 2.5M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Phathom Pharmaceuticals Inc. (PHAT) Prices 2.25M Share Common Offering at $42/Sh
December 17, 2020 6:14 AM ESTPhathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of... More
Phathom Pharmaceuticals (PHAT) PT Raised to $55 at Needham & Company
December 15, 2020 8:42 AM ESTNeedham & Company analyst Alan Carr raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $55.00 (from $45.00) while maintaining a Buy rating.
The analyst commented, "Phathom hosted a virtual R&D event and announced plans to initiate Phase 2 testing of vonoprazan in... More
Phathom Pharmaceuticals (PHAT) PT Raised to $36 at Goldman Sachs
December 11, 2020 9:09 AM ESTGoldman Sachs analyst Paul Choi raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $36.00 (from $32.00) while maintaining a Sell rating.... More
